Targeting of BRAF resistant melanoma via extracellular matrix metalloproteinase inducer receptor

The BRAF inhibitor Vemurafenib (PLX) has shown promise in treating metastatic melanoma, but most patients develop resistance to treatment after 6 months. We identified a transmembrane protein, extracellular matrix metalloproteinase inducer (EMMPRIN) as a cell surface receptor highly expressed by PLX...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Surg Res
Hlavní autoři: Zeiderman, Matthew R, Egger, Michael E, Kimbrough, Charles W, England, Christopher G, Dupre, Tess V, McMasters, Kelly M, McNally, Lacey R
Médium: Artigo
Jazyk:Inglês
Vydáno: 2014
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4576881/
https://ncbi.nlm.nih.gov/pubmed/24655664
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jss.2014.02.021
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky